Ferring Pharmaceuticals’s fecal microbiota transplant product looks to be facing an uphill battle for US Food and Drug Administration approval due in part to an FDA policy that complicated the company’s ability to conduct two placebo-controlled Phase III trials.
Rebyota, or RBX2660, will go before the agency’s Vaccines and Related Biological Products Advisory Committee on 22 September seeking approval...





